We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Celcuity Inc. is one of them. Celcuity Inc. (NASDAQ:CELC) is a clinical-stage biotechnology company developing targeted oncology therapies, with a focus on solid tumors such as advanced breast cancer. Its lead drug candidate, gedatolisib, targets the PI3K and mTOR pathways, key drivers of tumor growth and resistance, aiming to improve outcomes for patients with hormone receptor-positive (HR+), HER2-negative advanced ...

Core Insights - RenovoRx has expanded its commercial footprint to thirteen cancer centers approved to purchase its RenovoCath device, a significant increase from five centers in Q1 2025 [2][3] - The company has hired Philip Stocton as Senior Director of Sales and Market Development to enhance its commercialization strategy [4][6] - There is a growing clinical demand for localized solid tumor drug-delivery options, indicating a positive market trend for RenovoRx's offerings [3][5] Company Developments - Since launching commercial efforts in December 2024, RenovoRx has established a customer base of thirteen cancer centers, with four actively using RenovoCath and placing repeat orders [2][11] - The hiring of Philip Stocton, who has over 25 years of experience in MedTech sales, is expected to drive the company's commercialization efforts [4][6] - The company is focused on building sales momentum without significant capital outlays, indicating a strategic approach to growth [6] Product Information - RenovoCath is an FDA-cleared drug-delivery device designed for targeted therapeutic delivery, aiming to minimize systemic toxicity compared to traditional chemotherapy methods [8][9] - The device is currently being evaluated in the ongoing Phase III TIGeR-PaC trial, which could lead to additional customer acquisition post-enrollment completion [3][9] - RenovoRx's TAMP therapy platform, enabled by RenovoCath, aims to improve safety and efficacy for cancer patients [8][10]